The biotech is slashing a third of its workforce and more than half of its executive team in moves it called “necessary in ...

NKGen Biotech's CEO will present Phase 1 clinical trial results for NK cell therapy in Alzheimer's at AD/PD™ 2025. NKGen Biotech, Inc. announced that its CEO, Dr. Paul Y. Song, will present at ...

New York, USA, Feb. 28, 2025 (GLOBE NEWSWIRE) -- NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight The NK cell therapy market is experiencing ...

Nkarta is laying off a third of its employees, including half of the biotech’s executive leadership, as the company diverts ...

About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

The ongoing Phase 1 trial (ClinicalTrials.gov Identifier: NCT06699771) will enroll up to approximately 48 patients diagnosed with relapsed or refractory NK and T‑cell malignancies. The primary ...

With a storied history in vaccine development, India's Bharat Biotech is shaking things up and answering the call of advanced ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple ...